Search Results
May 12, 2026, 10:30 ET The $59B Quiet Shift Reshaping How Patients Access Care
VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).
More news about: Equity Insider
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
therapies for retinal disease and spinal cord injuries through its proprietary AlloSCOPE manufacturing platform. And MannKind Corporation (NASDAQ: MNKD) received FDA approval for updated prescribing information on Afrezza, its inhaled insulin, demonstrating the kind of regulatory progress that cell and
More news about: Equity Insider
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
platforms capable of a systemic re-rating. This emerging investment class includes Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASDAQ: MNKD), Altimmune (NASDAQ: ALT), Lineage Cell Therapeutics (NYSE-A: LCTX), and Arrowhead Pharmaceuticals (NASDAQ: ARWR).
More news about: USA News Group
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
the harsh side effects of traditional drugs. This regulatory shift positions Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASAQ: MNKD), Vertex Pharmaceuticals (NASDAQ: VRTX), Fate Therapeutics (NASDAQ: FATE), and Ardelyx (NADSAQ: ARDX) at the center of a massive
More news about: Equity Insider